The right Timing, right combination, right sequence, and right delivery for Cancer immunotherapy

Kwon, Minsu; Jung, Hanul; Nam, Gi Hoon; Kim, In San

doi:10.1016/j.jconrel.2021.01.009

Cited by 44 publications

(35 citation statements)

References 146 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among new TME targets, IAPs appear of great interest. 42 Combinations of immunotherapy and chemotherapy or target therapies are being widely investigated to overcome resistance to immunotherapy.…”

Section: Prognosis and Treatmentmentioning

confidence: 99%

“…Trials are ongoing investigating this approach, including a combination of avelumab, cetuximab and palbociclib. 42 A promising approach is to target the angiogenesis with multi-target kinase inhibitors and pembrolizumab (study LEAP-0.10; NCT04199104), or with angiopoietin inhibitors and immunotherapy. The rationale of this approach derives from the effect of anti-angiogenic therapies, which increase T-cell infiltration into tumors, reducing the immunosuppressive response and thereby overcoming resistance to checkpoint inhibitors.…”

Section: Prognosis and Treatmentmentioning

confidence: 99%

“…Trials are ongoing investigating this approach, including a combination of avelumab, cetuximab and palbociclib. 42 …”

Section: Prognosis and Treatmentmentioning

confidence: 99%

See 2 more Smart Citations

Further Understanding of the Immune Microenvironment in Head and Neck Squamous Cell Carcinoma: Implications for Prognosis

Denaro

Merlano

Nigro

2021

CMAR

View full text Add to dashboard Cite

We aimed to review the literature on the tumor microenvironment as a key player in tumor growth and anti-cancer treatment responses in head and neck cancer. Patients and Methods: We reviewed the recent literature on this topic, using the following research words: "tumor microenvironment" and "head and neck cancer or neoplasm or head and neck squamous cell carcinoma" and "immune cells" and "stromal cells". A search was conducted on the PubMed website and reports from international meetings, presentations and abstracts. Results: The tumor microenvironment is a complex network in which myeloid cells, tumoral cells, growth factors and cytokines are involved in angiogenesis, the extracellular matrix and epithelial-to-mesenchymal transition. Conclusion: Immune resistance and rapid tumor growth depend on immunosuppressive and pro-tumoral environments. Further investigations to classify and adequately treat patients with head and neck cancer are required.

show abstract

Section: Prognosis and Treatmentmentioning

confidence: 99%

Section: Prognosis and Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Further Understanding of the Immune Microenvironment in Head and Neck Squamous Cell Carcinoma: Implications for Prognosis

Denaro

Merlano

Nigro

2021

CMAR

View full text Add to dashboard Cite

show abstract

“…This process bridges the innate and adaptive immunity by priming T-cells to recognize tumor cells and have a killing effect. The elimination of apoptotic cells through phagocytosis was proven to be negatively regulated by RhoA/ROCK signaling, [ 131 ] and blocking the RhoA/ROCK pathway enhanced the phagocytic activities of macrophages [ 108 ]. Accordingly, use of ROCK inhibitor Y27632 increased the phagocytic activity of antigen presenting cells, inducing their tumor cell uptake and antigen presenting capability, proving that ROCK inhibition can effectively potentiate the innate immune response [ 132 ].…”

Section: Rock and Cancer Immunotherapymentioning

confidence: 99%

Rho-Kinase as a Target for Cancer Therapy and Its Immunotherapeutic Potential

Kim

Han

et al. 2021

IJMS

Self Cite

View full text Add to dashboard Cite

Cancer immunotherapy is fast rising as a prominent new pillar of cancer treatment, harnessing the immune system to fight against numerous types of cancer. Rho-kinase (ROCK) pathway is involved in diverse cellular activities, and is therefore the target of interest in various diseases at the cellular level including cancer. Indeed, ROCK is well-known for its involvement in the tumor cell and tumor microenvironment, especially in its ability to enhance tumor cell progression, migration, metastasis, and extracellular matrix remodeling. Importantly, ROCK is also considered to be a novel and effective modulator of immune cells, although further studies are needed. In this review article, we describe the various activities of ROCK and its potential to be utilized in cancer treatment, particularly in cancer immunotherapy, by shining a light on its activities in the immune system.

show abstract

“…One possible explanation is that when cancer cells escape from immune surveillance, the newly established tumors may have decreased cell surface MHC expression and/or experience antigen loss, thus enabling them to evade EV-mediated immune recognition. Moreover, the TME in tumor-bearing mice may be more conducive to sustained tumor growth [ 42 ], which could negatively influence the effector functions of infiltrated immune cells. To note, if the EV priming takes place after tumor establishment, those tumors might have already evolved and escaped from immune surveillance, leading to an unsuccessful antitumor immune response.…”

Section: Discussionmentioning

confidence: 99%

Bladder Cancer Extracellular Vesicles Elicit a CD8 T Cell-Mediated Antitumor Immunity

Ortiz-Bonilla

Uccello

Gerber

et al. 2022

IJMS

View full text Add to dashboard Cite

Tumor-derived extracellular vesicles (TEVs) play crucial roles in mediating immune responses, as they carry and present functional MHC-peptide complexes that enable them to modulate antigen-specific CD8+ T-cell responses. However, the therapeutic potential and immunogenicity of TEV-based therapies against bladder cancer (BC) have not yet been tested. Here, we demonstrated that priming with immunogenic Extracellular Vesicles (EVs) derived from murine MB49 BC cells was sufficient to prevent MB49 tumor growth in mice. Importantly, antibody-mediated CD8+ T-cell depletion diminished the protective effect of MB49 EVs, suggesting that MB49 EVs elicit cytotoxic CD8+ T-cell-mediated protection against MB49 tumor growth. Such antitumor activity may be augmented by TEV-enhanced immune cell infiltration into the tumors. Interestingly, MB49 EV priming was unable to completely prevent, but significantly delayed, unrelated syngeneic murine colon MC-38 tumor growth. Cytokine array analyses revealed that MB49 EVs were enriched with pro-inflammatory factors that might contribute to increasing tumor-infiltrating immune cells in EV-primed MC-38 tumors. These results support the potential application of TEVs in personalized medicine, and open new avenues for the development of adjuvant therapies based on patient-derived EVs aimed at preventing disease progression.

show abstract

The right Timing, right combination, right sequence, and right delivery for Cancer immunotherapy

Cited by 44 publications

References 146 publications

Further Understanding of the Immune Microenvironment in Head and Neck Squamous Cell Carcinoma: Implications for Prognosis

Further Understanding of the Immune Microenvironment in Head and Neck Squamous Cell Carcinoma: Implications for Prognosis

Rho-Kinase as a Target for Cancer Therapy and Its Immunotherapeutic Potential

Bladder Cancer Extracellular Vesicles Elicit a CD8 T Cell-Mediated Antitumor Immunity

Contact Info

Product

Resources

About